CN102083413B - 用于治疗高眼压和青光眼的方法和组合物 - Google Patents

用于治疗高眼压和青光眼的方法和组合物 Download PDF

Info

Publication number
CN102083413B
CN102083413B CN2009801197245A CN200980119724A CN102083413B CN 102083413 B CN102083413 B CN 102083413B CN 2009801197245 A CN2009801197245 A CN 2009801197245A CN 200980119724 A CN200980119724 A CN 200980119724A CN 102083413 B CN102083413 B CN 102083413B
Authority
CN
China
Prior art keywords
aqueous solution
antiseptic
polyethylene
container
eye drip
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN2009801197245A
Other languages
English (en)
Chinese (zh)
Other versions
CN102083413A (zh
Inventor
T.雷午那马基
P.彼利年
O.欧克沙拉
K.雷姆沙利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Santen Pharmaceutical Co Ltd
AGC Inc
Original Assignee
Asahi Glass Co Ltd
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39940592&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN102083413(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Asahi Glass Co Ltd, Santen Pharmaceutical Co Ltd filed Critical Asahi Glass Co Ltd
Publication of CN102083413A publication Critical patent/CN102083413A/zh
Application granted granted Critical
Publication of CN102083413B publication Critical patent/CN102083413B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN2009801197245A 2008-05-30 2009-05-28 用于治疗高眼压和青光眼的方法和组合物 Active CN102083413B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08397513.6 2008-05-30
EP08397513A EP2127638A1 (de) 2008-05-30 2008-05-30 Verfahren und Zusammensetzung zur Behandlung von Augenhochdruck und Glaukom
PCT/JP2009/060211 WO2009145356A1 (en) 2008-05-30 2009-05-28 Method and composition for treating ocular hypertension and glaucoma

Publications (2)

Publication Number Publication Date
CN102083413A CN102083413A (zh) 2011-06-01
CN102083413B true CN102083413B (zh) 2013-11-06

Family

ID=39940592

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801197245A Active CN102083413B (zh) 2008-05-30 2009-05-28 用于治疗高眼压和青光眼的方法和组合物

Country Status (27)

Country Link
US (3) US9999593B2 (de)
EP (7) EP2127638A1 (de)
JP (8) JP2011521943A (de)
KR (5) KR102246598B1 (de)
CN (1) CN102083413B (de)
AR (2) AR071937A1 (de)
AU (1) AU2009252210C1 (de)
BR (1) BRPI0913109B8 (de)
CA (2) CA2724194C (de)
CY (2) CY1115565T1 (de)
DK (4) DK3714877T3 (de)
EA (1) EA023661B1 (de)
ES (5) ES2907982T3 (de)
GE (1) GEP20156220B (de)
HR (4) HRP20220361T1 (de)
HU (3) HUE058079T2 (de)
JO (1) JO3039B1 (de)
LT (3) LT3205334T (de)
MX (1) MX2010012987A (de)
MY (1) MY159463A (de)
PL (4) PL2772249T3 (de)
PT (4) PT3714877T (de)
SG (1) SG191628A1 (de)
SI (4) SI2306977T1 (de)
TW (1) TWI432202B (de)
UA (1) UA102257C2 (de)
WO (1) WO2009145356A1 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI544927B (zh) 2008-03-17 2016-08-11 愛爾康研究有限公司 具有低濃度的表面活性劑以促進治療劑之生物可利用性的藥學組成物
EP2127638A1 (de) 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Verfahren und Zusammensetzung zur Behandlung von Augenhochdruck und Glaukom
EP2228058A1 (de) 2009-03-04 2010-09-15 Novagali Pharma S.A. Anionische Öl-in-Wasser-Emulsion mit Prostaglandinen und Verwendungen dafür
EP2389939A1 (de) 2010-05-28 2011-11-30 Novagali Pharma S.A. Verwendung von Prostaglandinen F2alpha und Analoga zur Heilung von Horn- und Bindehautläsionen
US20110136872A1 (en) * 2009-12-09 2011-06-09 Burk Robert M Stable aqueous compositions of prostglandin agonist prodrugs and methods for use thereof
JP5681472B2 (ja) * 2009-12-28 2015-03-11 ロート製薬株式会社 眼科用組成物
FR2961694B1 (fr) * 2010-06-29 2013-01-25 Thea Lab Systeme de delivrance polymerique d'une solution non visqueuse a base de prostaglandine sans conservateur
US9061034B2 (en) * 2010-07-29 2015-06-23 Allergan, Inc. Preservative free bimatoprost and timolol solutions
DK2598118T3 (en) 2010-07-29 2018-12-10 Allergan Inc CONSERVATIVE-FREE BIMATOPROST AND TIMOLOL SOLUTIONS
US20130245124A1 (en) * 2010-07-29 2013-09-19 Allergan, Inc. Preservative free bimatoprost solutions
SG187770A1 (en) 2010-08-12 2013-03-28 Univ Nanyang Tech A liposomal formulation for ocular drug delivery
ES2616089T3 (es) 2010-09-21 2017-06-09 S & V Technologies Gmbh Composición cosmética
EP2452669A1 (de) * 2010-10-29 2012-05-16 Omnivision GmbH Ophthalmische Zusammensetzung
CA2830896A1 (en) * 2011-04-12 2012-10-18 Yukihiko Mashima Aqueous ophthalmic composition
CN102716074B (zh) * 2012-06-28 2013-10-16 武汉武药科技有限公司 一种贝美前列素滴眼剂及其制备方法
PL2887923T3 (pl) 2012-08-24 2023-08-14 Sun Pharmaceutical Industries Limited Preparat okulistyczny polioksylipidu lub polioksylowego kwasu tłuszczowego i leczenie chorób oczu
US9956195B2 (en) 2014-01-07 2018-05-01 Nanyang Technological University Stable liposomal formulations for ocular drug delivery
CA2935957C (en) 2014-01-10 2023-01-03 Manistee Partners Llc Treatment of migraines using topical administration of prostaglandin f2alpha analogs
CN104766952B (zh) * 2015-04-21 2017-01-25 武汉凯迪工程技术研究总院有限公司 利用生物质气化炉滤渣制备锂离子电池负极材料的方法
PL3103439T3 (pl) 2015-06-09 2019-12-31 Medproject Pharma-Entwicklungs- Und Vertriebsgesellschaft Mbh Zdolny do tworzenia kropli oftalmiczny żel bimatoprostu
US10105371B2 (en) * 2015-10-09 2018-10-23 Tamara Vrabec Use of medications with neuroprotective properties to prevent or reduce the risk of ischemia-reperfusion injury in a subject
AU2016349833A1 (en) * 2015-11-06 2018-05-24 Accuitis Pharmaceuticals, Inc. Use of proteasome inhibitors to treat ocular disorders
EP3423076B1 (de) 2016-02-29 2024-04-17 Sun Pharmaceutical Industries Limited Topische cyclosporinhaltige formulierungen und verwendungen davon
GR1009040B (el) 2016-04-19 2017-05-19 Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων Φαρμακευτικο οφθαλμικο σκευασμα ελευθερο συντηρητικου
WO2018033854A1 (en) * 2016-08-15 2018-02-22 Santen Pharmaceutical Co., Ltd. Ophthalmic composition and a method for treating ocular hypertension and glaucoma
KR101770324B1 (ko) * 2016-11-09 2017-08-22 주식회사태준제약 안압 강하용 점안 조성물
JP2020059652A (ja) * 2016-12-26 2020-04-16 参天製薬株式会社 タフルプロストとクエン酸エステルとを含有するデポ剤
WO2018181294A1 (ja) * 2017-03-27 2018-10-04 興和株式会社 医薬製剤
US20180318319A1 (en) * 2017-05-04 2018-11-08 Ocular Science, Inc. Compositions and Methods for Treating Eyes and Methods of Preparation
JP6931493B2 (ja) 2017-06-22 2021-09-08 ヨンスン ファイン ケミカル カンパニー，リミテッド 緑内障治療用点眼組成物
TWI833535B (zh) * 2017-12-21 2024-02-21 日商參天製藥股份有限公司 賽佩普斯特(Sepetaprost)及Rho激酶抑制劑之組合醫藥
US20210282965A1 (en) 2018-07-09 2021-09-16 Warszawskie Zaklady Farmaceutyczne Polfa Sa Opthalmic dispensing device
CN111632025A (zh) * 2020-03-04 2020-09-08 吉林大学第一医院 一种贝美前列素眼用温度敏感型原位凝胶及其制备方法与应用
CN111840225B (zh) * 2020-08-12 2021-09-14 陈丽娜 一种用于治疗青光眼的滴眼剂及其制备方法
RU2761625C2 (ru) * 2021-02-11 2021-12-13 Общество с ограниченной ответственностью "Гротекс" (ООО "Гротекс") Фармацевтическая композиция тафлупроста
TW202400133A (zh) * 2022-03-25 2024-01-01 日商坪田實驗室股份有限公司 水性組成物
WO2023241652A1 (zh) * 2022-06-16 2023-12-21 广州润尔眼科生物科技有限公司 一种药物组合物及其制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1321144A1 (de) * 2000-09-13 2003-06-25 Santen Pharmaceutical Co., Ltd. Augentropfen

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4778815A (en) * 1987-03-18 1988-10-18 Ciba-Geigy Corporation Method of inhibiting cataracts by topical application of a 2-substituted 1,2-benzisoselenazol-3(2H)-one
EP0286903B2 (de) 1987-04-03 2000-03-29 The Trustees Of Columbia University In The City Of New York Anwendung eines Prostaglandins in Mischung mit einem adrenergischen Blocker zur Verminderung des Augen-Innendruckes
US5409125A (en) 1989-12-11 1995-04-25 Aktiebolaget Astra Unit dose container
DE4027320C2 (de) 1990-08-29 1993-09-30 Ursapharm Arzneimittel Gmbh Fluid-Abgabeeinrichtung für keimfreies Fluid
JPH0655640A (ja) 1992-08-04 1994-03-01 Aavan Internatl:Kk 洗面台カウンター及びその製造方法
JPH06107547A (ja) 1992-10-01 1994-04-19 Aarutetsuku Ueno:Kk 眼科用組成物
AU665287B2 (en) 1992-12-21 1995-12-21 Alcon Laboratories, Inc. Prostaglandin combinations in glaucoma therapy
JP2510066Y2 (ja) 1993-01-20 1996-09-11 東洋製罐株式会社 加熱殺菌可能な液体医薬容器
US5807892A (en) 1994-09-30 1998-09-15 Alcon Laboratories, Inc. Use of certain prostaglandin analogues to treat glaucoma and ocular hypertension
US5631287A (en) 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
EP1057486A1 (de) * 1995-11-17 2000-12-06 Alcon Laboratories, Inc. Verwendung einer Medikamentenkombination zur Behandlung von Glaukom
EP0930296B2 (de) 1996-09-17 2005-11-02 Asahi Glass Company Ltd. Fluorierte prostaglandinderivate und medikamente
EP0944530A1 (de) 1996-12-09 1999-09-29 Bausch & Lomb Incorporated Flexibler einweg-behälter
JP3480549B2 (ja) 1996-12-26 2003-12-22 参天製薬株式会社 ジフルオロプロスタグランジン誘導体およびその用途
AR002194A1 (es) 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.
CA2274708A1 (en) * 1997-10-13 1999-04-22 R-Tech Ueno, Ltd. Remedial composition for intraocular hypertension or glaucoma
US6066671A (en) 1997-12-19 2000-05-23 Alcon Laboratories, Inc. Treatment of GLC1A glaucoma with 3-benzoyl-phenylacetic acids, esters, or amides
GB2337740B (en) 1998-05-26 2000-11-15 Spreckelsen Mcgeough Ltd Fluid packaging
US6235781B1 (en) 1998-07-14 2001-05-22 Alcon Laboratories, Inc. Prostaglandin product
CN1146423C (zh) * 1998-07-14 2004-04-21 阿尔康实验室公司 前列腺素产品
BR9913955A (pt) 1998-09-25 2001-06-12 Alcon Lab Inc Composição oftalmológica confortável e de liberação sustentada e método para terapia ocular
US6096783A (en) 1998-12-15 2000-08-01 Alcon Laboratories, Inc. Cyclobutane prostaglandin analogues as ocular hypotensive agents
AU2183900A (en) 1998-12-24 2000-07-31 Alcon Laboratories, Inc. Ep4 receptor agonists for treatment of dry eye
EP1905757A1 (de) 1999-04-06 2008-04-02 Sepracor Inc. Derivate von Venlafaxin und Verfahren zu ihrer Herstellung und Verwendung
CA2413088C (en) 2000-06-19 2009-10-20 Kenji Morishima Preservative
JP3876355B2 (ja) * 2000-09-13 2007-01-31 参天製薬株式会社 点眼液
TW586946B (en) * 2000-12-22 2004-05-11 Novartis Ag Process to improve stability
WO2004006826A1 (ja) 2002-07-16 2004-01-22 Senju Pharmaceutical Co., Ltd. 薬液容器及びその製造方法
KR20050057251A (ko) 2002-09-09 2005-06-16 산텐 세이야꾸 가부시키가이샤 라타노프로스트를 유효 성분으로 하는 투명한 점안액
US7074827B2 (en) 2002-10-24 2006-07-11 Sucampo Ag (Usa) Inc. Method for treating ocular hypertension and glaucoma
DE602004024427D1 (de) * 2003-07-31 2010-01-14 Santen Pharmaceutical Co Ltd Prostaglandin enthaltendes produkt
US20050287325A1 (en) * 2004-06-25 2005-12-29 Pharmacia & Upjohn Company Pharmaceutical containers with low adsorption/absorption of active ingredients, and a method of testing materials for adsorption/absorption of active ingredients
DE602004017477D1 (de) * 2004-11-09 2008-12-11 Novagali Pharma Sa Öl-in-Wasser-Emulsion mit niedriger Konzentration des kationischen Mittels und positivem Zetapotential
US7562796B2 (en) 2004-11-24 2009-07-21 Holopack International Corp. Dispensing container with flow control system
KR101305649B1 (ko) 2004-12-09 2013-09-09 산텐 세이야꾸 가부시키가이샤 분자 내에 불소 원자를 갖는 프로스타글란딘 함유 제품
ATE555792T1 (de) 2004-12-24 2012-05-15 Santen Pharmaceutical Co Ltd Prostaglandin f2 alpha derivat enthaltende produkte
GB0501192D0 (en) * 2005-01-20 2005-03-02 Resolution Chemicals Ltd Stable prostaglandin-containing compositions
PL1905453T3 (pl) 2005-07-13 2013-02-28 Santen Pharmaceutical Co Ltd Kompozycja konserwująca do zastosowania okulistycznego
ES2460967T3 (es) 2005-08-02 2014-05-16 Santen Pharmaceutical Co., Ltd. Método para la prevención de la degradación de una sustancia térmicamente inestable
JP5247453B2 (ja) 2005-10-10 2013-07-24 ノバガリ ファルマ エスア プロスタグランジン含有眼科用カチオン性水中油型エマルジョン
FI126233B (sv) 2006-02-23 2016-08-31 Oy Kwh Mirka Ab Oscillerande slipmaskin
FR2918891B1 (fr) 2007-07-20 2009-09-25 Thea Sa Lab Solution ophtalmique a base de prostaglandines sans conservateur
KR100927617B1 (ko) 2007-11-26 2009-11-23 한국표준과학연구원 열분해 탄소 성분의 나노 크기를 가지는 바이오 센서의감지부를 제작하는 방법
EP2127638A1 (de) 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Verfahren und Zusammensetzung zur Behandlung von Augenhochdruck und Glaukom

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1321144A1 (de) * 2000-09-13 2003-06-25 Santen Pharmaceutical Co., Ltd. Augentropfen

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Emmanuelle Brasnu,et al.In vitro effects of preservative-free tafluprost and preserved latanoprost,travoprost,and bimatoprost in a conjunctival epithelial cell line.《Current eye research》.2008,第33卷(第4期),303-312. *

Also Published As

Publication number Publication date
PL2772249T3 (pl) 2017-10-31
ES2968837T3 (es) 2024-05-14
LT3205334T (lt) 2020-09-25
JP7265584B2 (ja) 2023-04-26
DK3714877T3 (da) 2022-02-14
PL2306977T3 (pl) 2015-01-30
DK3205334T3 (da) 2020-07-13
EP2772249B1 (de) 2017-05-03
HRP20220361T1 (hr) 2022-05-13
GEP20156220B (en) 2015-01-26
CY1115565T1 (el) 2017-01-04
AU2009252210A1 (en) 2009-12-03
AU2009252210B2 (en) 2014-10-16
CA2965185A1 (en) 2009-12-03
MX2010012987A (es) 2011-02-24
DK2772249T3 (en) 2017-07-17
KR102114401B1 (ko) 2020-05-25
BRPI0913109B8 (pt) 2021-05-25
KR101820816B1 (ko) 2018-01-22
ES2808050T3 (es) 2021-02-25
TW201000104A (en) 2010-01-01
AU2009252210C1 (en) 2016-04-14
JP2023085558A (ja) 2023-06-20
ES2627837T8 (es) 2018-02-26
JP2017178957A (ja) 2017-10-05
JP2021120412A (ja) 2021-08-19
JP6889789B2 (ja) 2021-06-18
US20110152264A1 (en) 2011-06-23
KR101988642B1 (ko) 2019-06-12
MY159463A (en) 2017-01-13
ES2495316T3 (es) 2014-09-17
TWI432202B (zh) 2014-04-01
EP4035656A1 (de) 2022-08-03
LT2772249T (lt) 2017-09-11
PT3205334T (pt) 2020-07-31
PT3714877T (pt) 2022-03-10
JP2016065095A (ja) 2016-04-28
DK2306977T3 (da) 2014-09-15
KR20190067272A (ko) 2019-06-14
PL3714877T3 (pl) 2022-05-16
WO2009145356A1 (en) 2009-12-03
JO3039B1 (ar) 2016-09-05
ES2627837T3 (es) 2017-07-31
HUE058079T2 (hu) 2022-06-28
EP2306977B1 (de) 2014-08-13
JP6356868B2 (ja) 2018-07-11
EA201071413A1 (ru) 2011-06-30
EP4289446A2 (de) 2023-12-13
JP6148317B2 (ja) 2017-06-14
HUE033103T2 (en) 2017-11-28
JP2020073574A (ja) 2020-05-14
SI2772249T1 (sl) 2017-08-31
AR071937A1 (es) 2010-07-28
KR20110011707A (ko) 2011-02-08
CY1120351T1 (el) 2019-07-10
EP2127638A1 (de) 2009-12-02
SI3714877T1 (sl) 2022-05-31
EA023661B1 (ru) 2016-06-30
US20180289618A1 (en) 2018-10-11
US10864159B2 (en) 2020-12-15
AR120961A2 (es) 2022-04-06
HUE049923T2 (hu) 2020-11-30
KR101650006B1 (ko) 2016-08-22
EP2772249A1 (de) 2014-09-03
KR20180008905A (ko) 2018-01-24
LT3714877T (lt) 2022-04-11
PL3205334T3 (pl) 2020-11-02
CA2724194A1 (en) 2009-12-03
EP3205334B1 (de) 2020-04-29
PT2772249T (pt) 2017-08-08
US20210059931A1 (en) 2021-03-04
HRP20170769T1 (hr) 2017-08-11
KR102246598B1 (ko) 2021-04-30
BRPI0913109A2 (pt) 2017-06-20
EP3714877B1 (de) 2022-01-26
KR20160102319A (ko) 2016-08-29
EP3205334A1 (de) 2017-08-16
BRPI0913109B1 (pt) 2019-10-22
EP4289446A3 (de) 2024-01-10
CA2724194C (en) 2017-06-27
JP6649992B2 (ja) 2020-02-19
EP4035656B1 (de) 2023-11-22
JP2011521943A (ja) 2011-07-28
ES2907982T3 (es) 2022-04-27
SI2306977T1 (sl) 2014-12-31
SI3205334T1 (sl) 2020-10-30
PT2306977E (pt) 2014-09-22
HRP20200998T1 (hr) 2020-10-16
EP2306977A1 (de) 2011-04-13
KR20200057801A (ko) 2020-05-26
JP2018154656A (ja) 2018-10-04
US9999593B2 (en) 2018-06-19
SG191628A1 (en) 2013-07-31
JP2014133765A (ja) 2014-07-24
HRP20140979T1 (hr) 2014-11-21
CN102083413A (zh) 2011-06-01
UA102257C2 (uk) 2013-06-25
EP3714877A1 (de) 2020-09-30

Similar Documents

Publication Publication Date Title
CN102083413B (zh) 用于治疗高眼压和青光眼的方法和组合物
JP2024079852A (ja) 高眼圧症及び緑内障を治療するための方法及び組成物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CP01 Change in the name or title of a patent holder

Address after: Osaka City, Osaka of Japan

Co-patentee after: AGC Corporation

Patentee after: Santen Pharmaceutical Co., Ltd.

Address before: Osaka City, Osaka of Japan

Co-patentee before: Asahi Glass Co., Ltd.

Patentee before: Santen Pharmaceutical Co., Ltd.

CP01 Change in the name or title of a patent holder